Literature DB >> 9298181

Anaphylactoid shock--a common cause of death in heroin addicts?

E Edston1, M van Hage-Hamsten.   

Abstract

We measured mast-cell tryptase in postmortem blood from 22 heroin addicts dying suddenly after injection. In 32%, the concentration of tryptase was elevated (> or = 10 micrograms/l), and the mean value of tryptase was significantly different from a control group dying from known, nonimmunologic causes (P < 0.05). The increased tryptase concentrations indicate that death was preceded by systemic mast-cell degranulation. All victims of drug deaths had morphine in blood, most below 0.2 microgram/ml. In 71% of the victims of drug-related deaths with tryptase values > or = 10 micrograms/l, the intermediate degradation product, 6-monoacetyl-morphine, was not found in blood, whereas this was the case in only two victims with values below that cutoff point. This indicates that those with high tryptase concentrations survived longer than those with lower values. No correlation was found between the IgE levels and tryptase in either group, supporting the hypothesis that tryptase release was not mediated by an allergic reaction. The well-known property of opiates to stimulate unspecifically the liberation of histamine and other constituents of mast-cell granules offers one explanation of our observations. The results suggest that many heroin fatalities are caused by an anaphylactoid reaction.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9298181     DOI: 10.1111/j.1398-9995.1997.tb01256.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  11 in total

Review 1.  Postmortem chemistry update part II.

Authors:  Cristian Palmiere; Patrice Mangin
Journal:  Int J Legal Med       Date:  2011-10-09       Impact factor: 2.686

2.  Mast cell tryptase and carboxypeptidase A expression in body fluid and gastrointestinal tract associated with drug-related fatal anaphylaxis.

Authors:  Xiang-Jie Guo; Ying-Yuan Wang; Hao-Yue Zhang; Qian-Qian Jin; Cai-Rong Gao
Journal:  World J Gastroenterol       Date:  2015-12-21       Impact factor: 5.742

3.  Accumulation of eosinophils, mast cells, and basophils in the spleen in anaphylactic deaths.

Authors:  Erik Edston
Journal:  Forensic Sci Med Pathol       Date:  2013-07-10       Impact factor: 2.007

4.  Mast cell tryptase in postmortem serum-reference values and confounders.

Authors:  Erik Edston; Olle Eriksson; Marianne van Hage
Journal:  Int J Legal Med       Date:  2006-05-19       Impact factor: 2.686

5.  Codeine induces human mast cell chemokine and cytokine production: involvement of G-protein activation.

Authors:  C H Sheen; R P Schleimer; M Kulka
Journal:  Allergy       Date:  2007-05       Impact factor: 13.146

6.  Bronchospasm precipitated by ethanol injection in arteriovenous malformation.

Authors:  Tiscia B Stefanutto; Van Halbach
Journal:  AJNR Am J Neuroradiol       Date:  2003 Nov-Dec       Impact factor: 3.825

Review 7.  Toxicities of opioid analgesics: respiratory depression, histamine release, hemodynamic changes, hypersensitivity, serotonin toxicity.

Authors:  Brian A Baldo
Journal:  Arch Toxicol       Date:  2021-05-11       Impact factor: 5.153

8.  MRGPRX2 Is the Codeine Receptor of Human Skin Mast Cells: Desensitization through β-Arrestin and Lack of Correlation with the FcεRI Pathway.

Authors:  Magda Babina; Zhao Wang; Saptarshi Roy; Sven Guhl; Kristin Franke; Metin Artuc; Hydar Ali; Torsten Zuberbier
Journal:  J Invest Dermatol       Date:  2020-10-13       Impact factor: 8.551

9.  Pathogenic role of cardiac mast cell activation/degranulation,TNF-alpha, and cell death in acute drug-related fatalities.

Authors:  Nasrin Perskvist; Carl Söderberg; Marianne van Hage; Erik Edston
Journal:  Vasc Health Risk Manag       Date:  2007

10.  Risk of anaphylaxis in opioid dependent persons: effects of heroin versus substitution substance.

Authors:  Ute Maurer; Carola Kager; Christina Fellinger; Dagmara Loader; Augustin Pollesböck; Bernhard Spitzer; Reinhart Jarisch
Journal:  Subst Abuse Treat Prev Policy       Date:  2014-02-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.